PARIS, France, February 7, 2024, 8:30 a.m. CET – Abivax SA (Euronext Paris and Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on the development of therapeutic treatments that exploit the mechanisms natural regulators of the body to stabilize the immune response in patients suffering from chronic inflammatory diseases, today announced the appointment of Ana Sharma as Vice President, Global Head of Quality. Ana Sharma has over 20 years of experience in the biopharmaceutical industry and extensive expertise in quality and GxP compliance. She has contributed to the marketing of more than 30 drugs in several therapeutic areas, notably gastroenterology and immunology. She has managed large international teams and interactions with regulatory authorities and their inspections globally.
Marc de Garidel, Managing Director of Abivax, said: “I am delighted to welcome Ana and that she now strengthens our team with her extensive experience in quality assurance in research and development within the biopharmaceutical sector. His expertise will be decisive in ensuring the smooth running of our ongoing and planned clinical studies as well as subsequent marketing authorization applications. »